To the Editor: In their systematic review and meta-analysis, Dr Kesselheim and colleagues1 assessed the equivalence of generic and brand-name drugs for cardiovascular disease. Several studies that I participated in were evaluated by the authors,2-4 and I generally agree with their conclusions. However, it is important to consider the limitations of current scientific evidence.
Carter BL. Equivalence of Generic and Brand-Name Drugs for Cardiovascular Disease. JAMA. 2009;301(16):1654–1656. doi:https://doi.org/10.1001/jama.2009.520
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: